Dr. Arjun Gupta and colleagues published a paper today entitled, ‘Use of Bone Modifying Agents Among Medicare Beneficiaries with Multiple Myeloma,’ in JAMA Oncology. In this video, Dr. Gupta reviews the paper and explains how the use of denosumab has skyrocketed in patients with multiple myeloma since its FDA approval in January 2018.
To read the paper, click here: https://jamanetwork.com/journals/jamaoncology/fullarticle/2757382
Study Explores Shift in Bone Medication for Multiple Myeloma,
Share This Post